Artiva Biotherapeutics, Inc.
ARTV
$9.62
$0.798.95%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/23/2026
-
Globe Newswire
6/16/2026
-
MarketBeat
6/12/2026
-
The Cerbat Gem
6/10/2026
-
The Cerbat Gem
6/8/2026
-
TipRanks
6/8/2026
-
TipRanks
6/8/2026
-
TipRanks: TheFly
6/8/2026
-
Globe Newswire
5/29/2026
-
PR Newswire
5/29/2026
-
CNW Group - News Releases
5/28/2026
-
The Cerbat Gem
5/28/2026
-
Globe Newswire
5/21/2026
-
Simply Wall St
5/21/2026
-
TipRanks Financial Blog
5/20/2026
-
The Cerbat Gem
5/20/2026
-
The Cerbat Gem
5/19/2026
-
Globe Newswire
5/19/2026
-
TipRanks Financial Blog
5/19/2026
-
Globe Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
5/14/2026
-
PR Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
5/14/2026
-
CNW Group - News Releases
5/11/2026
-
MarketBeat
5/11/2026
-
MarketBeat
5/9/2026
-
MarketBeat
5/9/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 10, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
(est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 267 4467
Address
5505 Morehouse Drive
San Diego, CA 92121
San Diego, CA 92121
Country
Year Founded
Business Description
Sector
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers...
more